| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Exit | 00 | $0 | – | 0 | +100.0% | 0.00% | – |
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| EPIZYME INC COM | 7 | Q2 2021 | 15.9% |
| NeoGenomics Inc | 7 | Q2 2021 | 8.7% |
| OrthoPediatrics Corp | 7 | Q2 2021 | 7.3% |
| Y-MABS THERAPEUTICS INC COM | 7 | Q2 2021 | 4.3% |
| CRINETICS PHARMACEUTICALS INC COM | 7 | Q2 2021 | 5.6% |
| G1 THERAPEUTICS INC COM | 7 | Q2 2021 | 7.3% |
| PTC THERAPEUTICS INC COM | 6 | Q1 2021 | 8.0% |
| CYTOKINETICS INC COM NEW | 6 | Q2 2021 | 4.9% |
| TURNING PT THERAPEUTICS INC COM | 6 | Q2 2021 | 6.7% |
| APELLIS PHARMACEUTICALS INC COM | 6 | Q1 2021 | 3.5% |
View Burrage Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Protalix BioTherapeutics, Inc.Sold out | July 30, 2021 | 0 | 0.0% |
| IVERIC bio, Inc. | February 14, 2020 | 10 | 3.4% |
View Burrage Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2021-11-15 |
| 13F-HR | 2021-08-16 |
| SC 13G/A | 2021-07-30 |
| 13F-HR | 2021-05-17 |
| 13F-HR | 2021-02-12 |
| SC 13G | 2021-02-12 |
| 13F-HR | 2020-11-13 |
| 13F-HR | 2020-08-14 |
| 13F-HR | 2020-05-14 |
| 13F-HR | 2020-02-14 |
View Burrage Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.